Osiris and Stryker enter strategic partnership to market Osiris’ viable bone matrix

135

Osiris Therapeutics has entered into an exclusive, worldwide partnership with Stryker Corporation for the commercialisation and development of Osiris’ viable bone matrix tissue form.

“This partnership combines the strengths of Stryker, an industry leader in marketing orthopaedic and spine products and of Osiris, the cellular regenerative medicine leader who developed this next generation viable bone matrix,” says Lode Debrabandere, president and chief executive officer of Osiris.

The agreement provides Stryker with exclusive, worldwide rights to Osiris’ viable bone matrix under the name BIO4. Osiris will be responsible for the manufacturing, continued research and product improvement activities while Stryker will be responsible for the commercialisation and marketing of BIO4.